Abstract
The current rise in the prevalence of Alzheimers disease (AD) is unfortunately not matched by new treatment options. In the last 10 years, epidemiological, preclinical and clinical data have enlightened the possible preventive action of omega-3 polyunsaturated fatty acids (n-3 PUFA) in AD and other diseases. While the contribution of recent studies to our general knowledge is priceless, many important new questions have been raised. In the present review, we aim at addressing some of these timely interrogations. First, the transport of n-3 PUFA across the blood-brain barrier is underscored based on preclinical data. Second, the relative contribution of two neuroactive n-3 PUFA found in fish oil, docosahexaenoic acid (DHA; 22:6 n-3) and eicosapentaenoic acid (EPA, 20:5 n-3), remains unclear and is reviewed. Third, clinical trials on neurodegenerative diseases consistently remind us that treating early is critical, and this is likely to be the case with n-3 PUFA in AD as well. Fourth, we draw attention to the possibility that the current knowledge translation approach to make health recommendations might have to be adapted to non-patentable endogenous compounds like n-3 PUFA. We propose that answers to these critical questions will be instrumental toward a rational use of n-3 PUFA in AD.
Keywords: Alzheimer, omega-3 polyunsaturated fatty acids, docosahexaenoic acid, eicosapentaenoic acid, blood-brain barrier, disease modification, knowledge translation, PUFA, placebo-controlled fashion, anti-inflammatory agent
Current Alzheimer Research
Title: Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers
Volume: 8 Issue: 5
Author(s): F. Calon
Affiliation:
Keywords: Alzheimer, omega-3 polyunsaturated fatty acids, docosahexaenoic acid, eicosapentaenoic acid, blood-brain barrier, disease modification, knowledge translation, PUFA, placebo-controlled fashion, anti-inflammatory agent
Abstract: The current rise in the prevalence of Alzheimers disease (AD) is unfortunately not matched by new treatment options. In the last 10 years, epidemiological, preclinical and clinical data have enlightened the possible preventive action of omega-3 polyunsaturated fatty acids (n-3 PUFA) in AD and other diseases. While the contribution of recent studies to our general knowledge is priceless, many important new questions have been raised. In the present review, we aim at addressing some of these timely interrogations. First, the transport of n-3 PUFA across the blood-brain barrier is underscored based on preclinical data. Second, the relative contribution of two neuroactive n-3 PUFA found in fish oil, docosahexaenoic acid (DHA; 22:6 n-3) and eicosapentaenoic acid (EPA, 20:5 n-3), remains unclear and is reviewed. Third, clinical trials on neurodegenerative diseases consistently remind us that treating early is critical, and this is likely to be the case with n-3 PUFA in AD as well. Fourth, we draw attention to the possibility that the current knowledge translation approach to make health recommendations might have to be adapted to non-patentable endogenous compounds like n-3 PUFA. We propose that answers to these critical questions will be instrumental toward a rational use of n-3 PUFA in AD.
Export Options
About this article
Cite this article as:
Calon F., Omega-3 Polyunsaturated Fatty Acids in Alzheimers Disease: Key Questions and Partial Answers, Current Alzheimer Research 2011; 8 (5) . https://dx.doi.org/10.2174/156720511796391881
DOI https://dx.doi.org/10.2174/156720511796391881 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Detection of Klebsiella Antibodies and HLA-B27 Allelotypes Could be Used in the Early Diagnosis of Ankylosing Spondylitis with a Potential for the Use of “Low Starch Diet” in the Treatment
Current Rheumatology Reviews Stem Cells and Translational Medicine: From Research to Clinical Procedures
Current Tissue Engineering (Discontinued) Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease
Current Medicinal Chemistry Teaching Pharmacogenetics in Low and Middle-Income Countries: Team Based Learning and Lessons Learned at the American University of Beirut
Current Pharmacogenomics and Personalized Medicine The Role of Phase Image in the Detection of Myocardial Dyskinesia by Magnetic Resonance Imaging (MRI)
Current Medical Imaging Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design The Contribution of Mannose Binding Lectin to Reperfusion Injury after Ischemic Stroke
Current Neurovascular Research Lipid Modulation of Intravascular and Cellular Sodium Handling:Mechanistic Insights and Potential Clinical Implications
Current Vascular Pharmacology Effects of Thiazolidinediones Beyond Glycaemic Control
Current Pharmaceutical Design Cardiovascular Disease Risk of Type 2 Diabetes Mellitus and Metabolic Syndrome: Focus on Aggressive Management of Dyslipidemia
Current Diabetes Reviews Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets